Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients.

@article{Bajetta1999DoubleblindRM,
  title={Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients.},
  author={Emilio Bajetta and Nicoletta Zilembo and Mitch Dowsett and L{\"o}ic Guillevin and Angelo di Leo and Luigi Celio and Antonella Martinetti and Alfonso Marchiano and Paola Pozzi and Simonetta Chiara Stani and Ettore Bichisao},
  journal={European journal of cancer},
  year={1999},
  volume={35 2},
  pages={208-13}
}
Letrozole is an orally competitive aromatase inhibitor. This double-blind, randomised, multicentre trial was carried out to evaluate the endocrine effects of two doses of letrozole, 0.5 mg versus 2.5 mg orally daily, in postmenopausal advanced breast cancer patients progressing after tamoxifen. The pharmacokinetics of letrozole was also assessed. 46 patients entered the trial, 22 on letrozole 0.5 mg and 24 on 2.5 mg. A significant suppression of oestrone and oestradiol levels was achieved by… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2002
View 2 Excerpts
Highly Influenced

New Generation Aromatase Inhibitors – from the Advanced to the Adjuvant Setting

Breast Cancer Research and Treatment • 2002
View 3 Excerpts
Highly Influenced

Anastrozole (Arimidex ™) – an aromatase inhibitor for the adjuvant setting?

British Journal of Cancer • 2001
View 1 Excerpt
Highly Influenced

Similar Papers

Loading similar papers…